Results 231 to 240 of about 199,032 (289)

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source

Prognostic Value of Neutrophil Percentage-Albumin Ratio in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. [PDF]

Curr Oncol
Eken E, Güneyin EA, Büyükkurt E, Yıldız F, Bilici M, Ayman CD.   +5 more
europepmc   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, EarlyView.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database. [PDF]

Front Immunol
Cao L, Wang Y, Dai P, Li X.
europepmc   +1 more source

IKKβ and USP28 Regulate HEY1 Stability to Promote Cancer Stemness and Immune Evasion in Hepatocellular Carcinoma

Advanced Science, EarlyView.
The uncovered IKKβ‐USP28‐HEY1 axis fuels cancer stemness and immune evasion in hepatocellular carcinoma. USP28 deubiquitinates HEY1 upon IKKβ‐mediated phosphorylation, conferring PD‐1/PD‐L1 blockade resistance. Pharmacological inhibition of USP28 sensitizes resistant tumors to anti‐PD‐1 immunotherapy, revealing a promising therapeutic strategy ...
Na Shao, Lin Zhang, Gufang Shen, Yangfan Lv, Tianshu Fang, Ya Cao, Qiongyi Zhang, Feng Xu, Chungang Liu   +8 more
wiley   +1 more source

Acetaminophen interactions with immune checkpoint inhibitors: guilt by association? [PDF]

J Immunother Cancer
de Lemos ML, de Lemos J, Kletas V, Latt R, Mucovic J.   +4 more
europepmc   +1 more source

Targeting KDM3B Elicits Anti‐tumor Immunity by Alleviating SHP1–mediated STING Suppression in Triple–Negative Breast Cancer

Advanced Science, EarlyView.
P3FI–90 treatment targets KDM3B, reshapes the epigenetic landscape, and suppresses SHP1 expression, thereby activating STING–TBK1–IRF3–type I IFN signaling pathway. Consequently, CD8+ T cells are recruited to the tumor site and activated to produce IFN–γ and GZMB, leading to the killing of TNBC cells.
Xiaolong Wang, Wenhao Li, Yifei Wang, Ning Zhang, Bing Chen, Wenjing Zhao, Lijuan Wang, Dan Luo, Qifeng Yang   +8 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies. [PDF]

Adv Sci (Weinh)
Chen F, Yu Y, Cai X, Lin J, Liang R, Kang R, Tang D, Liu J.   +7 more
europepmc   +1 more source

Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and Lysosome‐Targeted PD‐L1 Degradation

Advanced Science, EarlyView.
A rational design DNA nanoplatform not only achieves efficient PD‐L1 degradation but also triggers robust STING signaling. The nanodevice effectively reprograms “cold” tumors, leading to potent inhibition of tumor growth and metastasis in vivo. ABSTRACT The cGAS‐STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic ...
Haoxiang Li, Min Hou, Shasha Sun, Jun Cao, Jian‐Hui Jiang, Jianjun He   +5 more
wiley   +1 more source